Philip J Cheng1, Jeremy B Myers2. 1. Division of Urology, Department of Surgery, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA. 2. Division of Urology, Department of Surgery, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA. Jeremy.Myers@hsc.utah.edu.
Abstract
PURPOSE: To review the indications and techniques of augmentation cystoplasty (AC) in patients with neurogenic bladder (NGB) while also examining the long-term outcomes, complications, and follow-up surgeries. METHODS: PubMed/MEDLINE, Cochrane Library, and Embase databases were searched for articles related to AC and NGB. RESULTS: AC is indicated for an overactive or poorly compliant bladder refractory to conservative therapies, such as anticholinergic medications and bladder botulinum toxin injections. A variety of surgical techniques using gastrointestinal segments, alternative tissues, and synthetic materials have been described, though bowel remains the most durable. Ileocystoplasty is the most common type of AC, which uses a detubularized patch of ileum that is anastomosed to a bivalved bladder. Some patients undergo concomitant surgeries at the time of AC, such as catheterizable channel creation to aid with clean intermittent catheterization, ureteral reimplantation to treat vesicoureteral reflux, and bladder outlet procedure to treat incontinence. Following AC, the majority of patients experience an improvement in bladder capacity, compliance, and continence. Most patients also experience an improvement in quality of life. AC has significant complications, such as chronic UTIs, bladder and renal calculi, metabolic disturbances, bowel problems, perforation, and malignancy. AC also has a high rate of follow-up surgeries, especially if the patient undergoes concomitant creation of a catheterizable channel. CONCLUSIONS: Enterocystoplasty remains the gold standard for AC, though more research is needed to better evaluate the morbidity of different surgical techniques and the indications for concomitant surgeries. Experimental methods of AC with tissue engineering are a promising area for further investigation.
PURPOSE: To review the indications and techniques of augmentation cystoplasty (AC) in patients with neurogenic bladder (NGB) while also examining the long-term outcomes, complications, and follow-up surgeries. METHODS: PubMed/MEDLINE, Cochrane Library, and Embase databases were searched for articles related to AC and NGB. RESULTS: AC is indicated for an overactive or poorly compliant bladder refractory to conservative therapies, such as anticholinergic medications and bladder botulinum toxin injections. A variety of surgical techniques using gastrointestinal segments, alternative tissues, and synthetic materials have been described, though bowel remains the most durable. Ileocystoplasty is the most common type of AC, which uses a detubularized patch of ileum that is anastomosed to a bivalved bladder. Some patients undergo concomitant surgeries at the time of AC, such as catheterizable channel creation to aid with clean intermittent catheterization, ureteral reimplantation to treat vesicoureteral reflux, and bladder outlet procedure to treat incontinence. Following AC, the majority of patients experience an improvement in bladder capacity, compliance, and continence. Most patients also experience an improvement in quality of life. AC has significant complications, such as chronic UTIs, bladder and renal calculi, metabolic disturbances, bowel problems, perforation, and malignancy. AC also has a high rate of follow-up surgeries, especially if the patient undergoes concomitant creation of a catheterizable channel. CONCLUSIONS: Enterocystoplasty remains the gold standard for AC, though more research is needed to better evaluate the morbidity of different surgical techniques and the indications for concomitant surgeries. Experimental methods of AC with tissue engineering are a promising area for further investigation.
Authors: Pieter Dik; Aart J Klijn; Jan D van Gool; Catherine C E de Jong-de Vos van Steenwijk; Tom P V M de Jong Journal: Eur Urol Date: 2006-01-19 Impact factor: 20.096
Authors: Jan Groen; Jürgen Pannek; David Castro Diaz; Giulio Del Popolo; Tobias Gross; Rizwan Hamid; Gilles Karsenty; Thomas M Kessler; Marc Schneider; Lisette 't Hoen; Bertil Blok Journal: Eur Urol Date: 2015-08-22 Impact factor: 20.096
Authors: Roman Zachoval; Jiri Pitha; Eva Medova; Jiri Heracek; Martin Lukes; Miroslav Zalesky; Michael Urban Journal: Urol Int Date: 2003 Impact factor: 2.089
Authors: Jeremy B Myers; Sara M Lenherr; John T Stoffel; Sean P Elliott; Angela P Presson; Chong Zhang; Jeffery Rosenbluth; Amitabh Jha; DarshanP Patel; Blayne Welk Journal: Neurourol Urodyn Date: 2018-10-30 Impact factor: 2.696
Authors: Ingrid Garzón; Boris Damián Jaimes-Parra; Manrique Pascual-Geler; José Manuel Cózar; María Del Carmen Sánchez-Quevedo; María Auxiliadora Mosquera-Pacheco; Indalecio Sánchez-Montesinos; Ricardo Fernández-Valadés; Fernando Campos; Miguel Alaminos Journal: Polymers (Basel) Date: 2021-05-13 Impact factor: 4.329